M. H. Kollef, G. Sherman, S. Ward, and V. J. Fraser, Inadequate Antimicrobial Treatment of Infections, Chest, vol.115, issue.2, pp.462-474, 1999.

A. Rhodes, L. E. Evans, W. Alhazzani, M. M. Levy, M. Antonelli et al., Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016, Intensive Care Medicine, vol.43, issue.3, pp.304-377, 2017.

R. D. Moore, P. S. Lietman, and C. R. Smith, Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration, Journal of Infectious Diseases, vol.155, issue.1, pp.93-99, 1987.

. Eucast and . Aminoglycosides, Eucas, Pedro, 2011.

A. , Mise au point sur le bon usage de la spécialité Macugen®, solution injectable intra-vitréenne, Journal Français d'Ophtalmologie, vol.29, issue.8, pp.965-968, 2006.

R. Gálvez, C. Luengo, R. Cornejo, J. Kosche, C. Romero et al., Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity, International Journal of Antimicrobial Agents, vol.38, issue.2, pp.146-151, 2011.

E. De-montmollin, L. Bouadma, N. Gault, B. Mourvillier, E. Mariotte et al., Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen, Intensive Care Medicine, vol.40, issue.7, pp.998-1005, 2014.

F. Taccone, P. Laterre, H. Spapen, T. Dugernier, I. Delattre et al., Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock, Critical Care, vol.14, issue.2, p.R53, 2010.

W. Mayer and M. Schmiedecker, TLScompare, Proceedings of the 25th International Conference Companion on World Wide Web - WWW '16 Companion, 2016.

C. Cdc and . Nhsn, Surveillance Definitions for Specific Types of Infections

J. Blaser, C. König, R. Fatio, F. Follath, A. Cometta et al., Multicenter Quality Control Study of Amikacin Assay for Monitoring Once-Daily Dosing Regimens, Therapeutic Drug Monitoring, vol.17, issue.2, pp.133-136, 1995.

L. Gall, J. R. Lemeshow, S. Saulnier, and F. , A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study, JAMA, vol.270, pp.2957-63, 1993.

J. L. Vincent, R. Moreno, J. Takala, S. Willatts, A. De-mendonça et al., The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure, Intensive Care Medicine, vol.22, issue.7, pp.707-710, 1996.

C. Boidin, S. Jenck, L. Bourguignon, S. Torkmani, A. Roussey-jean et al., Determinants of amikacin first peak concentration in critically ill patients, Fundamental & Clinical Pharmacology, vol.32, issue.6, pp.669-677, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01953651

J. A. Roberts, M. H. Abdul-aziz, J. Lipman, J. W. Mouton, A. A. Vinks et al., Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions, The Lancet Infectious Diseases, vol.14, issue.6, pp.498-509, 2014.

N. Allou, A. Bouteau, J. Allyn, A. J. Snauwaert, D. Valance et al., Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock, Annals of Intensive Care, vol.6, issue.1, 2016.

C. Burdet, O. Pajot, C. Couffignal, L. Armand-lefèvre, A. Foucrier et al., Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia, European Journal of Clinical Pharmacology, vol.71, issue.1, pp.75-83, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01079022

O. Pajot, C. Burdet, C. Couffignal, L. Massias, L. Armand-lefevre et al., Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia, Journal of Antimicrobial Chemotherapy, vol.70, issue.5, pp.1487-1494, 2015.

, Eucas, Pedro, 2011.

C. Roger, B. Nucci, B. Louart, A. Friggeri, H. Knani et al., Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis, Journal of Antimicrobial Chemotherapy, vol.71, issue.1, pp.208-212, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01912185

S. De-winter, J. Wauters, W. Meersseman, J. Verhaegen, E. Van-wijngaerden et al., Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial, International Journal of Antimicrobial Agents, vol.51, issue.4, pp.562-570, 2018.

A. D. Kashuba, A. N. Nafziger, G. L. Drusano, and J. S. Bertino, Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria, Antimicrobial Agents and Chemotherapy, vol.43, issue.3, pp.623-629, 1999.

W. Duszynska, F. Taccone, M. Hurkacz, B. Kowalska-krochmal, A. Wiela-hoje?ska et al., Therapeutic drug monitoring of amikacin in septic patients, Critical Care, vol.17, issue.4, p.R165, 2013.

M. P. Mingeot-leclercq and P. M. Tulkens, Aminoglycosides: Nephrotoxicity, Antimicrobial Agents and Chemotherapy, vol.43, issue.5, pp.1003-1012, 1999.

, Note from the publisher

, Jurisdictional immunity of foreign States with regard to claims relating to infringements of obligations under peremptory norms